Our Pipeline - Research & Development

We continuously develop and expand our robust pipeline to address patients' unmet medical needs. Our pursuit of new medicines is fueled by the scientific curiosity of our employees, a willingness to examine new ideas, and the pairing of existing information with novel concepts.

Please note that the medicines in the pipeline below are currently under clinical trial investigation and are not yet approved.

Pipeline Chart

* As of Jan. 2023

Pipeline Chart

3 ADCs
Alpha

3 ADCs

Trastuzumab deruxtecan (T-DXd)
Patritumab deruxtecan (HER3-DXd)
Datopotamab deruxtecan (Dato-DXd)

AGA: actionable genomic alterations, BC: breast cancer, CRPC: castration-resistant prostate cancer, CRC: colorectal cancer, GC: gastric cancer,NSCLC: non-small celllung cancer, SCLC: small celllung cancer, TNBC: triple negative breast cancer

: Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
: Breakthrough designation (US)
: Orphan drug designation (JP)

Phase 1

(US/EU/Asia) HER2+ BC 2L+/ 1L
DESTINY-Breast07
(US/EU/Asia) HER2 low BC
Chemo naive/post chemo
DESTINY-Breast08
(JP/US/EU/Asia) HER2+ GC combo, 2L+/1L
DESTINY-Gastric03
(EU/Asia) HER2+ NSCLC
(durvalumab combo) 1L
DESTINY-Lung03
(US/EU) BC, bladder (nivolumab combo)
(US/EU) BC, NSCLC
(pembrolizumab combo)
(US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(JP/US) NSCLC, TNBC
BC*1, SCLC, GC,
urothelial, esophageal,
prostate, etc.
TROPION-PanTumor01
(CN) NSCLC, TNBC
TROPION-PanTumor02
(JP/US/EU/Asia) NSCLC
(w/o AGA, pembrolizumab
combo)
TROPION-Lung02
(JP/US/EU) NSCLC
(w/o AGA, durvalumab combo)
TROPION-Lung04
(JP/US/EU/Asia) solid tumors
(AZD5305 combo)
PETRA
(JP/US/EU/Asia) NSCLC
(JP/US) EGFR mutated
NSCLC (osimertinib combo)
(JP/US) HER3+ BC

Phase 2

(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(CN) HER2+ GC 3L
DESTINY-Gastric06
(JP/US/EU) HER2+ or HER2 mutant NSCLC 2L+
DESTINY-Lung01
(JP/US/EU/Asia) HER2 mutant NSCLC 2L+
DESTINY-Lung02
(CN) HER2 mutant NSCLC 2L+
DESTINY-Lung05
(US/EU/Asia) NSCLC
(durvalumab combo) 2L+
HUDSON
(JP/US/EU) HER2+ CRC 3L
DESTINY-CRC01
(JP/US/EU/Asia) HER2+ CRC 3L
DESTINY-CRC02
(JP/US/EU/Asia)
HER2 mutant tumor
DESTINY-PanTumor01
(US/EU/Asia)
HER2 expressing tumor
DESTINY-PanTumor02
(JP/US/EU/Asia) endometrial, ovarian, CRPC, GC, CRC combo
TROPION-PanTumor03
(JP/US/EU/Asia) NSCLC
(w/ AGA)
TROPION-Lung05
(US/EU/Asia) TNBC
(durvalumab combo)
BEGONIA
(JP/US/EU/Asia) EGFR mutated NSCLC
(osimertinib combo) 2L
ORCHARD
(JP/US/EU/Asia)
EGFR mutated NSCLC 3L
HERTHENA-Lung01

Phase 3

(JP/US/EU/Asia) HER2+ BC 3L
DESTINY-Breast02
(JP/US/EU/Asia) HER2+
BC adjuvant*2
DESTINY-Breast05
(JP/US/EU/Asia) HER2
low BC chemo naive
DESTINY-Breast06
(JP/US/EU/Asia) HER2+
BC 1L
DESTINY-Breast09
(JP/US/EU/Asia) HER2+
BC neoadjuvant
DESTINY-Breast11
(JP/EU/Asia) HER2+
GC 2L
DESTINY-Gastric04
(JP/US/EU/Asia) NSCLC (w/ HER2 exon 19 or exon 20 mutation) 1L
DESTINY-Lung04
(JP/US/EU/Asia) NSCLC 2/3L
TROPION-Lung01
(JP/US/EU/Asia) non-squamous NSCLC
(w/o AGA, pembrolizumab
combo) 1L
TROPION-Lung07
(JP/US/EU/Asia) NSCLC
(w/o AGA, pembrolizumab
combo) 1L
TROPION-Lung08
(JP/US/EU/Asia) BC*1 2/3L
TROPION-Breast01
(JP/US/EU/Asia) TNBC 1L
TROPION-Breast02
(JP/US/EU/Asia) TNBC
mono or durvalumab
combo) adjuvant*3
TROPION-Breast03
(JP/US/EU/Asia) EGFR mutated
NSCLC 2L
HERTHENA-Lung02

Submitted

(CN) HER2+ BC 2L
DESTINY-Breast03
(JP/CN) HER2 low BC
post chemo
DESTINY-Breast04
(JP/EU) HER2 mutant NSCLC 2L+
DESTINY-Lung01/Lung02

*1 HR+, HER2 low or negative BC
*2 Adjuvant therapy for HER2 positive breast cancer patients with residual invasive disease following neoadjuvant therapy
*3 Adjuvant therapy for TNBC patients with residual invasive disease following neoadjuvant therapy

Alpha

Oncology
Specialty Medicine
Vaccine

ALL: acute lymphoblastic leukemia, AML: acute myeloid leukemia, BCL: B cell lymphoma, CRPC: castration-resistant prostate cancer, DMD: Duchenne muscular dystrophy, ESCC: esophageal squamous cell carcinoma,FOP: Fibrodysplasia ossificans progressiva, LBCL: large B cell lymphoma, NSCLC: non small cell lung cancer, ES-SCLC: extensive stage-small cell lung cancer, PTCL: peripheral T-cell lymphoma

: Project in oncology that is planned to be submitted for approval in some countries/regions based on the results of phase 2 trials
: SAKIGAKE Designation (JP)
: Orphan drug designation (designated in at least one country/region among JP, US, and EU)

Phase 1

DS-7300 (JP/US)
B7-H3-directed ADC
ESCC, CRPC, squamous NSCLC, SCLC, etc.
DS-6000 (JP/US)
CDH6-directed ADC
Renal cell carcinoma, ovarian cancer
DS-1055 (JP/US)
Anti-GARP antibody
Solid tumors
DS-1594 (US)
Menin-MLL binding inhibitor
AML, ALL
DS-9606 (US/EU)
Target undisclosed ADC
Solid tumors
DS-6016 (JP)
Anti-ALK2 antibody
FOP
DS-7011 (US)
Anti-TLR7 antibody
Systemic lupus erythematosus
DS-2325 (US)
KLK5 inhibitor
Netherton syndrome

Phase 2

Valemetostat (DS-3201) (JP/US/EU/Asia)
EZH1/2 inhibitor
PTCL
Valemetostat (DS-3201) (EU)
EZH1/2 inhibitor
BCL
DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma
DS-7300 (JP/US/EU/Asia)
B7-H3-directed ADC
ES-SCLC
DS-5141 (JP)
ENA oligonucleotides DMD
DS-1211 (US/EU)
TNAP inhibitor
Pseudoxanthoma elasticum
DS-5670 (JP)
COVID-19 mRNA vaccine
COVID-19 (primary vaccination, 5 to 11 aged children) (in prep.)
VN-0200 (JP)
RS virus vaccine
RS virus infection

Phase 3

Pexidartinib (JP/Asia)
CSF-1/KIT/FLT3 inhibitor
Tenosynovial giant cell tumor
Esaxerenone (JP)
MR blocker
Diabetic nephropathy
VN-0102/JVC-001 (JP)
Measles mumps rubella
combined vaccine
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain)
COVID-19 (primary vaccination, adults)
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain)
COVID-19 (primary vaccination, 12 to 17 aged children)

Submitted

Quizartinib (JP/US/EU)
FLT3 inhibitor
AML 1L
Mirogabalin (CN)
α2δ ligands
Diabetic peripheral neuropathic pain
VN-0107/MEDI3250 (JP)
Live attenuated influenza vaccine nasal spray
DS-5670 (JP)
COVID-19 mRNA vaccine (original strain)
COVID-19 (booster vaccination)